4.4 Article

Fragment-Based Screen against HIV Protease

期刊

CHEMICAL BIOLOGY & DRUG DESIGN
卷 75, 期 3, 页码 257-268

出版社

WILEY
DOI: 10.1111/j.1747-0285.2009.00943.x

关键词

allosteric inhibitor; crystal structure; fragment screen; HIV protease; multidrug resistance

资金

  1. NIH [P01 GM083658-01]
  2. U.S. Department of Energy, Office of Basic Energy Sciences
  3. Department of Energy, Office of Biological and Environmental Research
  4. National Institutes of Health
  5. National Center for Research Resources
  6. Biomedical Technology Program
  7. National Institute of General Medical Sciences

向作者/读者索取更多资源

We have employed a fragment-based screen against wild-type (NL4-3) HIV protease (PR) using the Active Sight fragment library and X-ray crystallography. The experiments reveal two new binding sites for small molecules. PR was co-crystallized with fragments, or crystals were soaked in fragment solutions, using five crystal forms, and 378 data sets were collected to 2.3-1.3 angstrom resolution. Fragment binding induces a distinct conformation and specific crystal form of TL-3 inhibited PR during co-crystallization. One fragment, 2-methylcyclohexanol, binds in the 'exo site' adjacent to the Gly(16)Gly(17)Gln(18)loop where the amide of Gly(17) is a specific hydrogen bond donor, and hydrophobic contacts occur with the side chains of Lys(14) and Leu(63). Another fragment, indole-6-carboxylic acid, binds on the 'outside/top of the flap' via hydrophobic contacts with Trp(42), Pro(44), Met(46), and Lys(55), a hydrogen bond with Val(56), and a salt-bridge with Arg(57) . 2-acetyl-benzothiophene also binds at this site. This study is the first fragment-based crystallographic screen against HIV PR, and the first time that fragments were screened against an inhibitor-bound drug target to search for compounds that both bind to novel sites and stabilize the inhibited conformation of the target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据